Today: 29 April 2026
Browse Category

NASDAQ:PGEN 15 August 2025 - 14 November 2025

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen shares surged nearly 30% intraday on November 14, trading around $4.90–$5.00 after reporting Q3 revenue of $2.92 million, far above expectations. The company’s PAPZIMEOS therapy for recurrent respiratory papillomatosis is fully launched in the U.S., with over 100 patients enrolled and broad insurance coverage. Precigen has also filed for European approval of PAPZIMEOS.
14 November 2025
···
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

The FDA approved Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis, after trials showed 51.4% of adults avoided surgery for 12 months. Cardinal Health will acquire Solaris Health for $1.9 billion in cash, expanding its specialty care network. RemeGen’s telitacicept met its Phase 3 endpoint in primary Sjögren’s syndrome in China. Response Therapeutics’ RDX-002 pill curbed weight regain in a Phase 2 trial.
15 August 2025
···

Stock Market Today

  • Patrick Industries Inc. (PATK) Stock Price Analysis
    April 29, 2026, 4:00 PM EDT. Patrick Industries Inc. (PATK) stock prices and returns are tracked over various multi-year periods ending March 2021. Historical performance data, covering 1 to 4 years depending on start date, highlight cumulative returns but caution that past performance does not predict future results. The data comes from Gotrade Securities Inc., a licensed trading entity regulated under Labuan Financial Services and Securities Act 2010. Investments carry risks, including capital loss, and this information is general in nature, not tailored financial advice. It is not an offer to buy or sell securities, nor intended for U.S. residents or jurisdictions where prohibited. Investors should consider their own objectives and risk tolerance.

Latest article

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

29 April 2026
Vita Coco shares jumped 27% Wednesday after first-quarter net sales rose 37% to $180 million, beating analyst expectations. The company raised its 2026 revenue outlook to $720–$735 million and lifted adjusted EBITDA guidance. Diluted earnings reached $0.50 per share, up from $0.31 a year earlier. Gross margin improved to 39.9% despite higher logistics and tariff costs.
Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

29 April 2026
Marathon Petroleum shares rose 3.2% to $240.05 Wednesday as investors anticipated its May 5 earnings report, following a surge in fuel margins during the first quarter. Phillips 66 and Valero also gained after posting stronger-than-expected results. Marathon’s Robinson refinery in Illinois began planned maintenance in March. U.S. gasoline prices hit $4.18 a gallon, the highest since 2022, according to AAA.
Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

29 April 2026
MaxLinear shares rose about 34% to $69.58 on Wednesday after Loop Capital upgraded the stock and raised its target to $75. The surge followed a first-quarter report showing infrastructure revenue up 136% to become the company’s largest segment. Total revenue climbed 43% to $137.2 million. MaxLinear guided second-quarter revenue to $160–$170 million, citing strong demand for data-center optical products.
Go toTop